Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.

6533b7d8fe1ef96bd126af37

RESEARCH PRODUCT

Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.

Margus Viigimaa Michel Farnier Maurizio Averna Helena Vaverkova Philippe Brudi William Taggart Arvind Shah Qian Dong Luc Missault Amy O. Johnson-levonas

subject

Male Simvastatin Settore MED/09 - Medicina Interna Endocrinology Diabetes and Metabolism Ezetimibe Simvastatin Drug Combination Coronary Disease Gastroenterology chemistry.chemical_compound Risk Factors Drug Combination Azetidine Anticholesteremic Agent Odds Ratio Rosuvastatin Calcium Metabolic Syndrome education.field_of_study Sulfonamides Drug Substitution Metabolic Syndrome X Anticholesteremic Agents Lipid Middle Aged Lipids Europe Rosuvastatin Calcium Drug Combinations Cholesterol Treatment Outcome lipids (amino acids peptides and proteins)Female Cardiology and Cardiovascular Medicine medicine.drug Human medicine.medical_specialty Statin Logistic Model medicine.drug_class Population Hypercholesterolemia Sulfonamide Risk Assessment Ezetimibe Double-Blind Method Internal medicine Internal Medicine medicine Humans Rosuvastatin Least-Squares Analysis education Aged Apolipoproteins B Least-Squares Analysi Analysis of Variance Cholesterol business.industry Risk Factor Fluorobenzene nutritional and metabolic diseases Cholesterol LDL Fluorobenzenes Endocrinology Logistic Models Pyrimidines chemistry Pyrimidine Simvastatin Biological Marker Azetidines Ezetimibe/simvastatin Hydroxymethylglutaryl-CoA Reductase Inhibitor Hydroxymethylglutaryl-CoA Reductase Inhibitors business Biomarkers

description

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with ( n=368) and without ( n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.

year	journal	country	edition	language
2011-08-22	Diabetesvascular disease research

10.1177/1479164111418136 https://pubmed.ncbi.nlm.nih.gov/21859750